CANbridge Pharmaceuticals lands $43m Series E
China and Boston-based CANbridge Pharmaceuticals Inc, a developer of drugs to treat rare diseases and targeted cancers, has raised $43 million in Series E financing.
1 December 2020•1 min read
China and Boston-based CANbridge Pharmaceuticals Inc, a developer of drugs to treat rare diseases and targeted cancers, has raised $43 million in Series E financing.
Bites raises $40m Series A round to expand frontline worker learning platform
29 October 2026 · 7 mins read
OCIO Cerity seeks proof of exits as clients raise bar for venture funds
29 October 2026 · 4 mins read
Matter taps LPs that bring more than money for oversubscribed Fund II
28 October 2026 · 5 mins read
BackingMinds raises €50m for Fund III, focused on Nordic start-ups
26 October 2026 · 3 mins read
Singapore VC plants flag in Ohio in search of US investors
26 October 2026 · 6 mins read
New AI threats are fueling VC investment in cybersecurity
22 October 2026 · 4 mins read
Inspired Capital holds quick close on $450m for Fund IV
20 October 2026 · 4 mins read
